



## LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

May 6, 2024

UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA," or "Company"), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)

T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.

### Presentation Details

Format: Fireside Chat

Date: Monday, May 13, 2024

Time: 10:00 a.m. ET

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at <https://ir.lavatherapeutics.com/news-events/events>. The replay will be archived for 90 days following the presentation date.

### **About LAVA Therapeutics**

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.

A Phase 1/2a dose escalation trial ([NCT05369000](https://clinicaltrials.gov/ct2/show/study/NCT05369000)) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a trial evaluating monotherapy and with interleukin-2 (IL-2). The Company is also expanding the Phase 1/2a study to include a combination arm with KEYTRUDA®(pembrolizumab), through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs. For more information, please visit [www.lavatherapeutics.com](http://www.lavatherapeutics.com), and follow us on [LinkedIn](#), [X](#), and [YouTube](#).

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA

Gammabody® is a registered trademark of LAVA Therapeutics N.V.

### CONTACTS

Investor Relations

[ir@lavatherapeutics.com](mailto:ir@lavatherapeutics.com)

LifeSci Advisors (IR/Media)

Joyce Allaire

[Jallaire@lifesciadvisors.com](mailto:Jallaire@lifesciadvisors.com)